参考资料:[1] FDA grants priority review to efanesoctocog alfa for people with hemophilia A. Retrieved August 30, 2022 from https://www.news.sanofi.us/press-releases?item=137377[2] Konkle et al., (2020). BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. NEJM, DOI: 10.1056/NEJMoa2002699